Intelligence Feed event · Policy · 2026-09-24

    HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMO

    Question

    HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMO

    Direct answer

    HUTCHMED announced the presentation of clinical data from two Phase III trials of savolitinib combined with osimertinib at the ESMO Congress 2026 in Madrid. The global SAFFRON study and China-based SANOVO study both demonstrated statistically significant and clinically meaningful efficacy in non-small cell lung cancer (NSCLC) patients. Developed in partnership with AstraZeneca, the combination regimen aims to treat EGFR-mutated lung cancer patients who develop MET-amplified resistance mechanisms following first-line therapy.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-24
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMO”, revision 1, evidence through 2026-09-24. https://marketontology.com/market-events/2026-09-24/hutchmed-and-astrazeneca-present-phase-iii-lung-cancer-data-at-esmo-a0a387

    POLICY
    HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMO
    HUTCHMED announced the presentation of clinical data from two Phase III trials of savolitinib combined with osimertinib at the ESMO Congress 2026 in Madrid. The global SAFFRON study and China-based SANOVO study both demonstrated statistically significant and clinically meaningful efficacy in non-small cell lung cancer (NSCLC) patients. Developed in partnership with AstraZeneca, the combination regimen aims to treat EGFR-mutated lung cancer patients who develop MET-amplified resistance mechanisms following first-line therapy.
    HCMAZN
    Impact
    67
    SEP 24
    SIG
    85%
    HCMAZN
    HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMO
    HUTCHMED announced the presentation of clinical data from two Phase III trials of savolitinib combined with osimertinib at the ESMO Congress 2026 in Madrid. The global SAFFRON study and China-based SANOVO study both demonstrated statistically significant and clinically meaningful efficacy in non-small cell lung cancer (NSCLC) patients. Developed in partnership with AstraZeneca, the combination regimen aims to treat EGFR-mutated lung cancer patients who develop MET-amplified resistance mechanisms following first-line therapy.
    → Statistically significant Phase III combination data with osimertinib expands Tagrisso line extension potential, supporting AZN oncology revenue projections.
    Impact
    HUTCHMED announced the presentation of clinical data from two Phase III trials of savolitinib combined with osimertinib at the ESMO Congress 2026 in Madrid. The global SAFFRON study and China-based SANOVO study both demonstrated statistically significant and clinically meaningful efficacy in non-small cell lung cancer (NSCLC) patients. Developed in partnership with AstraZeneca, the combination regimen aims to treat EGFR-mutated lung cancer patients who develop MET-amplified resistance mechanisms following first-line therapy.
    Affected
    HCMAZN
    Transmission
    Statistically significant Phase III combination data with osimertinib expands Tagrisso line extension potential, supporting AZN oncology revenue projections.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    HCMoncology clinical validation and milestone recognition from AstraZeneca partnershipUp1-5dHUTCHMED announced presentation of positive Phase III SAFFRON and SANOVO data at ESMO 2026.
    AZNexpansion of osimertinib combination indications in lung cancer oncology franchiseUp1-4wAstraZeneca partners with HUTCHMED on savolitinib in combination with osimertinib.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    HCMUpagreed13.90 2026-09-24+0.29%+4.82%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month